Study Evaluating Venlafaxine ER in Patients With Panic Disorder
The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in comparison to those of placebo.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00044772
|Study Director:||Medical Monitor, MD||Wyeth is now a wholly owned subsidiary of Pfizer|